We Develop
Life Changing Medicines

for Patients Living With Autoimmune Diseases

Our mission is to bring life-changing therapeutic benefits to patients living with autoimmune diseases.

A new era of CAR T-cell therapy

Kyverna is pioneering CAR T-cell therapies for autoimmune disease patients by harnessing the power of T cells to achieve a potentially sustained treatment-free remission by resetting the immune system.

Bringing the transformational experience of cell therapies to autoimmune diseases

We believe the success of CAR T-cell therapies in B cell-driven hematological malignancies can be leveraged to deliver therapeutic benefits in patients living with autoimmune diseases.

A patient-centric approach

We are a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.


Chimeric antigen receptor (CAR) T-cell therapies


Autologous (KYV-101) and allogeneic

Disease Target

B cell-driven autoimmune diseases

Clinical Trials

Lupus nephritis Systemic sclerosis Myasthenia gravis Multiple sclerosis

Clinical trials

Participation in clinical trials is the best way to access our investigational product. Kyverna may consider requests for expanded access when alternative therapy options have been exhausted.